Global Oncolytic Virus Immunotherapy Market Opportunity and Clinical Trials Insight 2030

  • No. of Pages: 420
  • Publish Date: May-2024
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only


Global Oncolytic Virus Immunotherapy Market Opportunity and Clinical Trials Insight 2030 Report Highlights:


  • Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion By 2030
  • Oncolytic Viruses Immunotherapies Clinical Trials By Company, Indication and Phase
  • Comprehensive Insight On Oncolytic Virus Immunotherapies In Clinical Trials: > 180 Therapies
  • FDA and EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME
  • Patent Analysis Therapies in Clinical Trials
  • IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis
  • Platforms Used For Developing Advanced Oncolytic Virus Immunotherapy


Cancer endures to be a relentless adversary, challenging both patients and the medical community across the world. The quest of innovative and targeted therapies to battle against this multifaceted disease has led to remarkable advancements in the field of cancer therapy. Amidst the many emerging strategies, oncolytic virus immunotherapy has captured the attention of researchers and clinicians as a promising avenue for cancer treatment in the recent years. The realm of oncolytic virus immunotherapy harnesses the natural characteristics of viruses to selectively target and destroy cancer cells, offering a unique and precision oriented approach to treatment. As this therapeutic paradigm progresses from the realm of scientific discovery to commercial viability, it brings forth a multitudinous of opportunities and challenges that shape the dynamics of the commercial market.


Hitherto, 3 oncolytic virus immunotherapies, namely Oncorine (H101), Imlygic (Talimogene laherparepvec), and teserpaturev (G47∆; Delytact), have been approved over the preceding decennium for the treatment of different types of cancer like head and neck cancer, melanoma and malignant glioma. However, it is expected that the domain will observe many more approvals in the upcoming years because of that fact that a handful of advanced oncolytic virus immunotherapies such as Oncos 102, CAN-2409, Pelareorep, CG070, VG161 have received designations like Fast Track, Orphan Drug, PRIME from regulatory agencies, FDA and EMA.


In the clinical field, oncolytic viruses are at the forefront of innovative research and therapeutic development. These viruses, carefully engineered or selected for their innate oncolytic properties, are designed to infiltrate cancer cells, replicate within them, and induce their destruction while simultaneously stimulating an immune response. Moreover, as the sphere of oncolytic virus immunotherapy surpasses the confines of laboratories and clinical trials, its journey into the commercial arena is characterized by an involvement of pharma companies that will aid to shape its trajectory in the global cancer treatment landscape.


The triumph of other immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, has generated considerable interest in harnessing the immune system to fight cancer. Oncolytic virus immunotherapy complements these approaches by utilizing viruses to stimulate an immune response against cancer cells. The positive outcomes from these immunotherapies have fueled interest in leveraging the immune system to combat cancer, leading to increased exploration of oncolytic virus immunotherapy as a complementary and synergistic approach.


On that account, multiple studies are ongoing in the clinical pipeline which comprise the combinations of oncolytic viruses with different types of antibodies targeting immune checkpoint receptors such as delolimogene mupadenorepvec with atezolizumab, OH2 injection, with or without irinotecan or HX008, ADV/HSV-tk with Pembrolizumab, for the treatment of patients suffering from wide array of cancer subtypes such as pancreatic cancer, Gastrointestinal Cancer, breast cancer etc.


Competition from the involvement of multitudinous pharmaceutical companies such as Merck, Bristol-Myers Squibb, Astellas Pharma, Roche, Lokon Pharma, NRG oncology, CG oncology, Genemedicine, Binhui Biopharmaceutical Barinthus Biotherapeutics, TILT Biotherapeutics, Genelux Corporation, Replimune, and Candel Therapeutics have created wave in the commercial market of oncolytic virus immunotherapy. As a result, the clinical development landscape will observed several pharmaceuticals companies commencing research in order to understand the oncolytic virus mode of actions which will aid to develop advanced and innovative oncolytic virus immunotherapy with least possible side effects.


It is projected that the market of oncolytic virus immunotherapy is poised to expand and multiply further in the forthcoming years due to the augmenting government regulatory approvals in conjugation with snow balling investments, collaborations and partnerships in the pharmaceutical sector. As of May 2024, the oncolytic virus is crowded by usage of different types of oncolytic virus like herpes simplex type-1 virus (HSV-1) or adenoviruses with or without chemotherapy, monoclonal antibodies directing against PD-1 and PD-L1 receptors, therapeutic peptide vaccines or nanoparticles in order to optimize delivery and performance for cancer treatments.


Currently, the US remains the market leader of the market as evident from rising collaborations, advancement and government bestow. The synergy between these clinical and commercial aspects propels the field forward, offering new expectation to cancer patients and shaping the future of cancer treatment. Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy. As research further delves deeper into understanding the complexities of this innovative approach, there is optimism that oncolytic viruses will emerge as a valuable addition for cancer treatments, offering new avenues for improved outcomes and enhanced quality of life for patients.

oncolytic virus immunotherapy Oncolytic Virotherapy oncolytic virus therapy oncolytic virus treat cancer treatment oncolytic virus  examples  oncolytic virus delivery oncolytic virus replication selectivity oncolytic virus cost oncolytic virus approved oncolytic virus research oncolytic virus study oncolytic virus clinical trials oncolytic virus gene therapy oncolytic virus success rate oncolytic virus indications oncolytic virus diseases oncolytic virus therapy market oncolytic virus melanoma oncolytic virus benefits oncolytic virus clinical landscape oncolytic virus working oncolytic virus development advances oncolytic virus review virus therapy virology oncolytic virus novel approach oncolytic virus approved oncolytic virus need oncolytic virus glioma brain tumor oncolytic virus pancreatic cancer oncolytic virus ovarian cancer oncolytic virus lymphoma oncolytic virus lung cancer  SCLC oncolytic virus breast cancer tnbc oncolytic virus prostate cancer oncolytic virus hepatocellular cancer oncolytic virus platform technology oncolytic virus companies oncolytic virus combinations oncolytic virus nanoparticles oncolytic virus chemotherapy oncolytic virus  hemotherapeutic drugs oncolytic virus peptides oncolytic virus targeted therapies oncolytic virus future opportunity avenueoncolytic virus regulatory designations oncolytic virus fda oncolytic virus ema oncolytic virus safety efficacy oncolytic virus progress challenges oncolytic virus market oncolytic virus sales oncolytic virus Imlygic oncolytic virus Amgen oncolytic virus  alimogene laherparepvec oncolytic virus t-vec oncolytic virus Oncorine H101 oncolytic virus China NMPA oncolytic virus Shenzhen SiBiono GeneTech oncolytic virus Delytact Oncolytic virus third generation oncolytic virus teserpaturev oncolytic virus G47 oncolytic virus HSV-1 oncolytic virus Japan MHLW oncolytic virus latest breakthrough oncolytic virus news oncolytic virus  ollaborations oncolytic virus patents oncolytic virus Immune System stimulation oncolytic virus Checkpoint Combo oncolytic virus tumor warm up hot engineered virus recombinant virus oncolytic virus early promising result oncolytic virus mechanism oncolytic virus Kalivir oncolytic virus calidi oncolytic virus renovo oncolytic virus ValoTx Valo Therapeutics oncolytic virus transgene oncolytic virus imugene oncolytic virus epicentrx oncolytic virus genelux oncolytic virus new era Paradigm Oncolytic  mmunoViroTherapy engineering strategies enhance oncolytic virus oncolytic virus genetically genetic 

Need custom market research solution? We can help you with that too.